Teon Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
555 Twin Dolphin Dr Ste 120, Redwood Cit...Phone Number
(650) 486-1902Website
www.teontherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Teon Therapeutics
Teon Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor micro-environment.Explore more
Teon Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Teon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Teon Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Teon Therapeutics
Check out if Teon Therapeutics is spiking on competitors!
Earning: See what the market has to say on Teon Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Teon Therapeutics has new funding data
Teon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Teon Therapeutics had a recent Job posting/layoffs
Check if Teon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Teon Therapeutics
Compare insights from companies similar to Teon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Teon Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Teon Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Teon Therapeutics.
Teon Therapeutics financials insights
Gather financial insights about Teon Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Series A
$30M
Teon Therapeutics Tech Stack
A closer look at the technologies used by Teon Therapeutics
Most Recent Scoops
New Hire
Executive Move
Lateral Move
Executive Move
Teon Therapeutics has announced that Lina Yao has transitioned from the role of Interim Chief Executive Officer, Chief Scientific Officer & Founder to the role of Chief Scientific Officer & Founder.
Funding
Funding
Teon Therapeutics has received an SBA PPP loan for $150,000 from Silicon Valley Bank, supporting the retention of 7 jobs.
Management Move
Executive Move
Executive Moves, New Hire, Promotion
Teon Therapeutics News & Media
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors
SAN FRANCISCO--(BUSINESS WIRE)-- #CB2Receptor--The first patient has been treated in Teon's Phase 1/2 clinical trial evaluating TT-816, an oral immune checkpoint inhibitor, in advanced solid tumorsTeon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816
SAN FRANCISCO--(BUSINESS WIRE)-- #CEO--Teon's novel oral cannabinoid CB2 receptor antagonist immune checkpoint inhibitor, TT-816, has IND accepted by FDA to begin Ph 1/2 clinical trial.Teon Therapeutics Names Serge Messerlian as CEO | Business Wire
Teon Therapeutics names Serge Messerlian as CEO, and announces first patient dosed in Phase 1/2 clinical trial of TT-702.Teon Therapeutics Names Serge Messerlian as CEO
SAN FRANCISCO--(BUSINESS WIRE)-- #A2Breceptor--Teon Therapeutics names Serge Messerlian as CEO, and announces first patient dosed in Phase 1/2 clinical trial of TT-702.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Teon Therapeutics
Sign Up For FreeTo access detailed company insights
Teon Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor micro-environment.... Read More
